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Abstract
Given the poor prognosis of pediatric patients with relapsed or refractory sarcomas, discovery and 
implementation of innovative approaches and tools to guide therapy are urgent needs. This 
retrospective pilot study evaluated the impact of relapse and refractory therapies aligned with 
molecular characterization of biopsies collected at the time of primary diagnosis.
RESULTS
Molecular profile-based drug selection for relapse or refractory therapy using tumor 
collected at diagnosis may not predict overall survival
In part 1 of the analysis, two subjects received therapies aligned with the genomic diagnostic 
recommended therapies (score of 1). Six subjects did not receive any therapies 
recommended or contraindicated based on the molecular testing results or received both 
recommended and potentially contraindicated therapies (score of 0). One subject received a 
potentially contraindicated therapy (score of –1; Supplementary Table S1 online). A Cox 
regression analysis revealed no linear trend in overall survival (hazard ratio = 0.8; P = 0.79) 
among subjects who received therapies (1) consistent with tumor molecular testing, (2) 
inconsistent, or (3) potentially contraindicated therapies (Figure 1a).
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In part 2 of the analysis, five subjects received at least one therapy aligned with the genomic 
diagnostic results (score of 1). Four subjects received therapies not aligned with the 
molecular diagnostic results (score of 0; Supplementary Table S1 online). The Cox 
regression analysis revealed no difference in overall survival (hazard ratio = 1.41; P = 0.66) 
between subjects who received relapse or refractory therapies consistent with tumor 
molecular testing and those who received therapies not aligned with molecular testing results 
(Figure 1b).
Molecular profile of relapsed tumor sample shows different genetic profile and drug 
recommendations
Although the analysis above was performed using the tumor molecular testing from 
specimens obtained at or near a subject’s diagnosis, one subject also had tumor molecular 
testing performed on a specimen representing relapsed or refractory disease. This was an 11-
year-old male with a pulmonary relapse of osteosarcoma who had tumor molecular profiling 
done on both a specimen from diagnosis as well as a specimen from relapse. Compared to 
the specimen collected at diagnosis, the relapse specimen shows additional cyclin E1 and 
MYC copy number gains, elevated mRNA expression of TOPO IIa, and a decreased 
expression of carbonic anhydrase IX (Figure 2). Hence, there were new drugs indicated by 
molecular analysis of the relapse specimen, such as doxorubicin and bevacizumab, which 
were not provided by analysis of the initial diagnosis specimen alone.
DISCUSSION
Although there is great optimism that the use of a precision medicine approach in pediatric 
patients with aggressive cancers will improve patient outcomes, there are challenges and 
caveats to this method. In this retrospective pilot study, we found that subjects who received 
therapies aligned with tumor molecular testing from specimens obtained at original 
diagnosis in the setting of relapsed or refractory disease did not have improved overall 
survival. Furthermore, the molecular diagnostic analyses of tumor specimens from diagnosis 
and relapse from a single subject revealed different results associated with distinct drug 
recommendations between the two samples. Given the shift in malignant cell biology after 
exposure to chemotherapy, it stands to reason that obtaining a tumor sample from relapsed 
or metastatic disease sites for molecular testing and ultimately guiding therapeutic decision-
making is paramount.
As this was a retrospective study, therapy decisions for the eight deceased patients were not 
driven by the molecular diagnostic profiles; the profiles for this exploratory pilot study were 
obtained after their deaths. Prospective studies are ongoing to assess whether molecular 
testing guided therapy will further improve the efficacy of the therapy. In addition, further 
studies with larger sample sizes and additional outcome measures are required to fully 
elucidate and define the impact of using a precision medicine approach for therapeutic 
decision-making in pediatric patient populations.
Carter et al. Page 2
Clin Pharmacol Ther. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
METHODS
This study was approved by the Indiana University School of Medicine Institutional Review 
Board (#1501467439). A retrospective review of the medical records and molecular 
diagnostic analysis from nine pediatric subjects with relapsed, refractory, or rare sarcomas 
was completed. The molecular diagnostic analysis was performed using specimens obtained 
at or near a subject’s diagnosis. Eight of the specimens were samples collected at diagnosis 
and one of the specimens was from a local control surgery 3.5 months after the subject’s 
initial diagnosis. Eight of the nine subjects were deceased at the time of analysis.
Molecular diagnostic results were obtained using a Clinical Laboratory Improvement 
Amendment-approved, next-generation sequencing cancer diagnostic test. Recommended 
and potentially contraindicated cancer therapies provided in the test report are based upon 
the individual’s tumor genetic variants, copy number variants, gene fusions, mRNA 
expression, and protein expression. These recommendations are supported by literature on 
known biomarker/drug associations and published therapeutic investigations. Potentially 
contraindicated therapies are defined as those drugs that will likely not provide clinical 
benefit. The therapeutic recommendations resulting from the clinical molecular diagnostic 
results were compared to the cancer therapies each subject received and the outcome of 
overall survival was ascertained.
In part 1 of the analysis, subjects were assigned a score of 1 if they received at least one 
molecular diagnostic recommended therapy and no potentially contraindicated therapies. A 
score of –1 was assigned if a subject received at least one therapy that was potentially 
contraindicated and no therapies aligned with the molecular testing results. A score of 0 was 
assigned if a subject did not receive any recommended or contraindicated therapies or 
received both recommended and contraindicated therapies.1
In part 2 of the analysis, the potentially contraindicated therapies were excluded from 
scoring of the subjects. A score of 1 was assigned if a subject received at least one therapy 
aligned with the molecular diagnostic recommended therapies. If a subject did not receive 
any recommended therapies, he or she received a score of 0.1
Two Kaplan-Meier overall survival curves for the nine subjects were plotted by the 
“survival” package in R software. A Cox regression analysis was used to test and estimate 
the hazard ratio for the linear trend of score (1, 0, –1) in the first analysis. In the part 2 
analysis, the hazard ratio was tested and estimated between score 1 and 0.
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Figure 1. 
Kaplan-Meier curves of overall survival. (a) Score of 1 indicates a subject received at least 
one drug aligned with the molecular diagnostic testing results and no potentially 
contraindicated therapies. Score of −1 indicates a subject received at least one therapy that 
was potentially contraindicated and no therapies aligned with testing results. Score of 0 
indicates a subject did not receive drugs aligned with or contraindicated by molecular 
diagnostic testing results or received both recommended and contraindicated therapies. (b) 
Score of 1 indicates a subject received at least one drug aligned with the molecular 
diagnostic testing results. Score of 0 indicates a subject did not receive any drugs aligned 
with the molecular diagnostic testing results.
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Figure 2. 
A subject with tumor molecular profiling at diagnosis and relapse.
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